Has Rakesh Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $787 in general payments to Rakesh Patel, MD across 36 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rakesh Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rakesh Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rakesh Patel, MD

Otolaryngology · Paramus, NJNPI 1457312589

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Optinose US, Inc. at 44.1% of the total. Reporting peaked in 2021 at $302 and has fallen 77.3% since, to $69 in 2025. That places this record below the midpoint for otolaryngology clinicians in NJ, where the typical reported total is $1,314.

$787in general payments, 2019–2025

Across 36 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Optinose US, Inc.$347
Regeneron Healthcare Solutions, Inc.$122
GSK$50
Lilly USA, LLC$44
Intersect ENT, Inc.$39
Merck$32
plus $153 from 8 others

$25,000in ownership & investment interests, 2019–2025

Across 7 payments — averaging $3571.43 each. An ownership or investment interest held by the physician or an immediate family member.

Gramercy Extremity Orthopedics LLC$25K

What the payments were for

Food & beverage$787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Optinose US, Inc.	9	$347
Regeneron Healthcare Solutions, Inc.	8	$122
GSK	3	$50
Lilly USA, LLC	2	$44
Intersect ENT, Inc.	2	$39
Merck	2	$32
Alk-abello, Inc	2	$31
Acclarent, Inc	2	$26
Stryker	1	$19
Aerin Medical Inc.	1	$16
Medtronic	1	$16
AbbVie	1	$15
Hikma Pharmaceuticals USA	1	$15
Sanofi	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Xhance$248

How this compares

$787 in reported general payments places this provider in the 40th percentile of 232 otolaryngology providers in New Jersey.

See all otolaryngology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$197,673

Medicare patients

446

Services billed

1,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Mometasone Furoate	113	$7,627
Azelastine Hcl	44	$1,522
Pantoprazole Sodium	127	$1,494
Fluocinolone Acetonide Oil	41	$1,453
Fluticasone Propionate	92	$1,331
Ofloxacin	25	$934
Ipratropium Bromide	24	$875
Famotidine	77	$863
Cefdinir	29	$401
Omeprazole	35	$303
Levocetirizine Dihydrochloride	27	$270
Prednisone	100	$259
Mupirocin	52	$206
Montelukast Sodium	14	$176

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Paramus

Nishant ReddyEast Windsor$133K
Giant LinFlorham Park$25K
Samir ShahVoorhees$16K
Brian BensonHackensack$14K
Andrew BlitzerHackensack$9K
Ahmad MahmoudClifton$9K
Jean EloyNewark$8K
Ramtin KassirWayne$8K
Wayne HsuehNewark$7K
Gregory SmithEvesham$7K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →